Author Archives: Joana Carvalho

Myozyme Effectiveness in LOPD Fades Over Time, Real-world Study Finds

In the first years of treatment, Myozyme (alglucosidase alfa) — marketed in the U.S. as Lumizyme — can effectively increase physical endurance, and improve lung function and muscle strength in adults with late-onset Pompe disease (LOPD), a real-world study found. Yet, despite this treatment, patients’ clinical outcomes, particularly lung…

Novel Mouse Model of Pompe Shows Potential of New Gene Therapy

Scientists have created a new mouse model of Pompe disease that displays the severe respiratory impairments experienced by many patients but were never observed in other animal models of the disorder. Using this more stringent model, investigators also demonstrated the therapeutic potential of a new form of gene…